Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 78Carcinoma, Non-Small-Cell Lung 43Nasopharyngeal Carcinoma 24Lung Neoplasms 23Breast Neoplasms 14Cholangiocarcinoma 13Lymphoma, Large B-Cell, Diffuse 12Neoplasm Metastasis 11Ovarian Neoplasms 10Lymphoma, Extranodal NK-T-Cell 10Recurrence 9Biliary Tract Neoplasms 9Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Nasopharyngeal Neoplasms 6Lymphoma 6Lymphoma, T-Cell, Peripheral 5Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rectal Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Gallbladder Neoplasms 4Colonic Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma of Lung 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell 3

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Resectable Biliary Tract Cancer × Gemcitabine × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡